Patient Cloud AppConnect

Patient Cloud AppConnect

With the creation of Apple ResearchKit, Software Development Kits (SDKs) are becoming part of the language of innovation in life sciences and healthcare. Medidata is excited about the potential for new mobile tools emerging  in the clinical trial space, and understands issues around security and privacy, along with challenges like  regulatory compliance, subject de-identification, and full audit trails that require special consideration.

About AppConnect

Medidata AppConnect, part of the Medidata Patient Cloud, and provides a way to easily plug a new or existing app into your clinical trial for data capture. This regulatory-compliant software enables rapid deployment of mobile apps without requiring detailed clinical trial expertise.

  • Gather and process data from nearly any type of application
  • Developers build mobile app front-ends while Medidata manages backend dataflow
  • Compatible with Apple ResearchKit and other third-party toolsets
  • Supports iOS and Android mobile app development
  • Authentication, encrypted local data storage and synchronization with Medidata’s backend
  • Supports CFR Part 11-compliant ingestion of mobile health device data, with a unified audit trail

Medidata AppConnect provides a regulatory-compliant backend for the newest mobile patient engagement experiences that will support the patient-centric trials of today. Count on Medidata to be your partner in innovation.

About the AppConnect Partner Program

Medidata partners with experienced app development companies who are pre-certified to build using AppConnect. AppConnect Partners represent premier companies who have successfully built clinical research apps on iOS, Android, and other platforms.

Please also refer to mHealth.works

For more information

Get Started

Medidata’s services team and Services Partners can help get your trial up and running quickly.

Quickly gain know-how in the platform through Medidata Academy’s extensive courses and flexible training formats.

Questions? Contact us.